$256.37 0.00 (%) Pharmacyclics Inc - NASDAQ

Mar. 26, 2015 | 04:00 PM

Partner Headlines

  1. Top Funds Buying Rackspace, Allergan ogen Idec, Apple

    IBD | Mar. 3, 2015 | 18:50PM EST
  2. Leerink: Pharmacyclics Is Now Worth $240

    Benzinga | Mar. 3, 2015 | 15:33PM EST
  3. Wedbush Downgrades Pharmacyclics To Neutral

    Benzinga | Mar. 3, 2015 | 08:15AM EST
  4. Big Cap 20 Reflecting Market Leadership

    IBD | Mar. 2, 2015 | 18:44PM EST
  5. Weekly Analyst Highlights: Oil, Tesla On Readers' Minds

    Benzinga | Feb. 27, 2015 | 16:49PM EST
  6. In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody

    Benzinga | Feb. 27, 2015 | 14:31PM EST
  7. Benzinga's Top Downgrades

    Benzinga | Feb. 27, 2015 | 09:21AM EST
  8. Credit Suisse Downgrades Pharmacyclics To Neutral

    Benzinga | Feb. 27, 2015 | 08:33AM EST
  9. Credit Suisse Downgrades Pharmacyclics Amid Takeover Rumors

    Benzinga | Feb. 26, 2015 | 10:08AM EST
  10. Benzinga's M&A Chatter for Wednesday February 25, 2015

    Benzinga | Feb. 25, 2015 | 21:26PM EST
  11. Pharmacyclics hits new high

    IBD | Feb. 25, 2015 | 18:51PM EST
  12. Deutsche Bank On Pharmacyclics: 'We Do Not See Much Upside'

    Benzinga | Feb. 25, 2015 | 17:05PM EST
  13. Pharmacyclics Rumor: How Some Wall Street Analysts Are Reacting

    Benzinga | Feb. 25, 2015 | 14:47PM EST
  14. Biotech Pharmacyclics Spikes On Buyout Rumors

    IBD | Feb. 25, 2015 | 14:31PM EST
  15. Biotech Stocks Moving Higher

    Benzinga | Feb. 23, 2015 | 15:35PM EST
  16. Stocks Edge Lower, Oil Falls, But Managed-Care Firms Shine

    IBD | Feb. 23, 2015 | 11:47AM EST
  17. Weekly 52-Week Highs Highlight: DG, AGN, ADSK, AVGO, PCYC

    GuruFocus | Feb. 22, 2015 | 18:55PM EST
  18. Nomura Recap of Stocks to Look Out For

    Benzinga | Feb. 19, 2015 | 20:01PM EST
  19. Analysts Respond To Pharmacyclics' Q4 Results

    Benzinga | Feb. 19, 2015 | 14:25PM EST
  20. Why Today's Stock Market Action Is Encouraging

    IBD | Feb. 19, 2015 | 11:55AM EST
  21. Nomura Upgrades Pharmacyclics, Sees 'Upside' To Stock

    Benzinga | Feb. 19, 2015 | 09:42AM EST
  22. Benzinga's Top Downgrades

    Benzinga | Feb. 19, 2015 | 09:07AM EST
  23. JP Morgan Downgrades Pharmacyclics To Neutral

    Benzinga | Feb. 19, 2015 | 08:16AM EST
  24. Leukemia Drug Boosts Sales

    IBD | Feb. 18, 2015 | 18:22PM EST
  25. Actavis Leads IBD 50 Stocks With Earnings This Week

    IBD | Feb. 14, 2015 | 08:02AM EST
  26. JMP Securities Covers Mostly Good News From Pharma Pending More Visibility

    Benzinga | Feb. 11, 2015 | 07:54AM EST
  27. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD | Feb. 10, 2015 | 10:30AM EST
  28. Stocks That Battle Cancer Were The Best-Performing Biotechs In January

    Benzinga | Jan. 30, 2015 | 13:03PM EST
  29. IBD 50 Turns In Solid Week As Market Uptrend Resumes

    IBD | Jan. 23, 2015 | 18:34PM EST
  30. 10 Biotech Stories You Might've Missed This Week

    Benzinga | Jan. 15, 2015 | 13:18PM EST
  31. Imbruvica lifts Pharmacyclics

    IBD | Jan. 13, 2015 | 18:51PM EST
  32. Mid-Day Market Update: Pharmacyclics Surges On Strong Preliminary 2014 Results; Fresh Market Shares Slip

    Benzinga | Jan. 13, 2015 | 13:24PM EST
  33. Mid-Morning Market Update: Markets Open Higher; Alcoa Profit Beats Expectations

    Benzinga | Jan. 13, 2015 | 11:30AM EST
  34. Pharmacyclics Soars As Imbruvica Sales Beat Estimates

    IBD | Jan. 13, 2015 | 11:29AM EST
  35. Benzinga's Volume Movers

    Benzinga | Jan. 13, 2015 | 10:36AM EST
  36. Morning Market Gainers

    Benzinga | Jan. 13, 2015 | 09:49AM EST
  37. Tuesday Morning Movers: ChannelAdvisor Plummets

    Benzinga | Jan. 13, 2015 | 09:29AM EST
  38. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  39. UPDATE: BTIG Initiates Coverage On Pharmacyclics

    Benzinga | Jan. 6, 2015 | 07:38AM EST
  40. IMBRUVICA Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients

    Benzinga | Jan. 5, 2015 | 09:02AM EST
  41. At Pharmacyclics, Employees Train To Become Geniuses

    IBD | Jan. 2, 2015 | 16:27PM EST
  42. Toys, Department Stores Rock, But Biotechs Tumble

    IBD | Dec. 23, 2014 | 12:06PM EST
  43. Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma

    Benzinga | Dec. 9, 2014 | 09:02AM EST
  44. AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate Imbruvica In Hematologic Cancers

    Benzinga | Nov. 4, 2014 | 14:35PM EST
  45. Wainwright Sees TG Therapeutics As Take-Out Target

    Benzinga | Oct. 27, 2014 | 13:20PM EST
  46. Pharmacyclics Enters Into Agreement With Roche To Evaluate IMBRUVICA And GAZYVA In Lymphoma And Leukemia

    Benzinga | Oct. 16, 2014 | 14:47PM EST
  47. Pharmacyclics and Servier Agree To Conclude Pan-HDAC Inhibitor Collaboration

    Benzinga | Sep. 25, 2014 | 16:02PM EST
  48. Gilead's Zydelig Approved In EU; Imbruvica In Wings

    IBD | Sep. 19, 2014 | 12:17PM EST
  49. UPDATE: Morgan Stanley Reiterates On Pharmacyclics, Inc. Following VA Contract News

    Benzinga | Sep. 11, 2014 | 09:53AM EST
  50. Pharmacyclics Price Target Cut On Higher Spending

    IBD | Sep. 8, 2014 | 13:02PM EST
Trading Center